The secretory proprotein convertases furin, PC5, and PC7 activate VEGF-C to induce tumorigenesis

Journal of Clinical Investigation

Volumn 111, Issue 11, 2003, Pages 1723-1732

  Siegfried, Geraldine ^a   Basak, Ajoy ^b   Cromlish, James A ^a   Benjannet, Suzanne ^a   Marcinkiewicz, Jadwiga ^a   Chrétien, Michel ^b   Seidah, Nabil G ^a   Khatib, Abdel Majid ^b  

^a CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

^b OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTITRYPSIN; ALPHA 2 MACROGLOBULIN; FURIN; GLUTAMINYLVALYLHISTIDYLSERYLISOLEUCYLISOLEUCYLARGINYLARGINYLSERYLLEUCYLPROL INE; HISTIDYLSERYLISOLEUCYLISOLEUCYLARGINYLARGINYLSERYLLEUCINE; HISTIDYLSERYLISOLEUCYLISOLEUCYLSERYLSERINE; PC5 PROTEIN; PC7 PROTEIN; PROPROTEIN CONVERTASE; PROTEIN; PROTEIN PACE4; PROTEINASE; PROVASCULOTROPIN C; SECRETORY PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN C; CARBAMIC ACID DERIVATIVE; ENDOTHELIAL CELL GROWTH FACTOR; MESSENGER RNA; OLIGOPEPTIDE; PCSK7 PROTEIN, HUMAN; PCSK7 PROTEIN, MOUSE; RECOMBINANT PROTEIN; SUBTILISIN; TETRAPEPTIDE CARBAMATE;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER; CANCER CELL CULTURE; CARCINOGENESIS; CHO CELL; COLON CARCINOMA; CONTROLLED STUDY; EMBRYO DEVELOPMENT; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN MOTIF; PROTEIN PROCESSING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TISSUE; TUMOR GROWTH; ANIMAL; BINDING SITE; CELL CULTURE; CELL TRANSFORMATION; DOSE RESPONSE; GENETIC TRANSFECTION; HAMSTER; IMMUNOHISTOCHEMISTRY; KINETICS; METABOLISM; MUTATION; NEOPLASM; PEPTIDE SYNTHESIS; PROTEIN TERTIARY STRUCTURE; SERODIAGNOSIS; TIME; WESTERN BLOTTING;

AMINO ACID MOTIFS; ANIMALS; BINDING SITES; BLOTTING, WESTERN; CARBAMATES; CELL TRANSFORMATION, NEOPLASTIC; CHO CELLS; CRICETINAE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL GROWTH FACTORS; FURIN; HUMANS; IMMUNOHISTOCHEMISTRY; KINETICS; MUTATION; NEOPLASMS; OLIGOPEPTIDES; PEPTIDE BIOSYNTHESIS; PRECIPITIN TESTS; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SUBTILISINS; TIME FACTORS; TRANSFECTION; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR C;

EID: 0038481179     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI200317220     Document Type: Article

References (43)

1. Joukov, V., et al. 1996. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. [erratum 1996, 15:1751] EMBO J. 15:290-298.
2. Huang, H.Y., Ho, C.C., Huang, P.H., and Hsu, S.M. 2001. Co-expression of VEGF-C and its receptors, VEGFR-2 and VEGFR-3, in endothelial cells of lymphangioma. Implication in autocrine or paracrine regulation of lymphangioma. Lab. Invest. 81:1729-1734.
3. Karkkainen, M.J., Makinen, T., and Alitalo, K. 2002. Lymphatic endothelium: a new frontier of metastasis research. Nat. Cell Biol. 4:E2-E5.
4. Joukov, V., et al. 1997. Proteolytic processing regulates receptor specificity and activity of VEGF-C. EMBO J. 16:3898-3911.
5. Seidah, N.G., and Chretien, M. 1999. Proprotein and prohormone convertases: a family of subtilases generating diverse bioactive polypeptides. Brain Res. 848:45-62.
6. Khatib, A.M., Siegfried, G., Chretien, M., Metrakos, P., and Seidah, N.G. 2002. Proprotein convertases in tumor progression and malignancy: novel targets in cancer therapy. Am. J. Pathol. 160:1921-1935.
7. Benjannet, S., et al. 2001. Post-translational processing of beta-secretase (beta-amyloid-converting enzyme) and its ectodomain shedding. The pro- and transmembrane/cytosolic domains affect its cellular activity and amyloid-beta production. J. Biol. Chem. 276:10879-10887.
8. Khatib, A.M., et al. 2001. Inhibition of proprotein convertases is associated with loss of growth and tumorigenicity of HT-29 human colon carcinoma cells: importance of insulin-like growth factor-1 (IGF-1) receptor processing in IGF-1-mediated functions. J. Biol. Chem. 276:30686-30693.
9. Takahashi, S., et al. 1993. A mutation of furin causes the lack lack of precursor-processing activity in human colon carcinoma LoVo cells. Biochem. Biophys. Res. Commun. 195:1019-1026.
10. Basak, A., Zhong, M., Munzer, J.S., Chretien, M., and Seidah, NG. 2001. Implication of the proprotein convertases furin, PC5 and PC7 in the cleavage of surface glycoproteins Hong Kong, Ebola and respiratory syncytial viruses: a comparative analysis with fluorogenic peptides. Biochem. J. 353:537-545.
11. Zhong, M., er al. 1999. The prosegments of furin and PC7 as potent inhibitors of proprotein convertases. In vitro and ex vivo assessment of their efficacy and selectivity. J. Biol. Chem. 274:33913-33920.
12. Basak, A., Chretien, M., and Seidah, N.G. 2002. A rapid fluorometric assay for the proteolytic activity of SKI-1/S1P based on the surface glycoprotein of the hemorrhagic fever Lassa virus. FEBS Lett. 514:333-339.
13. Kyriazis, A.P., et al. 1982. Human pancreatic adenocarcinoma line Capan-1 in tissue culture and the nude mouse: morphologic, biologic, and biochemical characteristics. Am. J. Pathol. 106:250-260.
14. Jean, F., et al. 1998. alphal-Antitrypsin Portland, a bioengineered serpin highly selective for furin: application as an antipathogenic agent. Proc. Natl. Acad. Sci. U. S. A. 95:7293-7298.
15. Kukk, E., et al. 1996. VEGF-C receptor binding and pattern of expression with VEGFR-3 suggests a role in lymphatic vascular development. Development. 122:3829-3837.
16. Nakayama, K. 1997. Furin: a mammalian subtilisin/Kex2p-like endoprotease involved in processing of a wide variety of precursor proteins. Biochem. J. 327:625-635.
17. Seidah, N.G., and Chretien, M. 1999. Proprotein and prohormone convertases: a family of subtilases generating diverse bioactive polypeptides, Brain Res. 848:45-62.
18. Lissitzky, J.C., et al. 2000. Endoproteolytic processing of integrin pro-alpha subunits involves the redundant function of furin and proprotein convertase (PC) 5A, but not paired basic amino acid converting enzyme (PACE) 4, PCSB or PC7. Biochem. J. 346:133-138.
19. Uchida, K., Chaudhary, L.R., Sugimura, Y., Adkisson, H.D., and Hruska, K.A. 2003. Proprotein convertases regulate activity of prostate epithelial cell differentiation markers and are modulated in human prostate cancer cells. J. Cell. Biochem. 88:394-399.
20. Zheng, M., Streck, R.D., Scott, R.E., Seidah, N.G., and Pintar, J.E. 1994. The developmental expression in rat of proteases furin, PC1, PC2, and carboxypeptidase E: implications for early maturation of proteolytic processing capacity. J. Neurosci. 14:4656-4673.
21. Lymboussaki, A., Olofsson, B., Eriksson, U., and Alitalo, K. 1999. Vascular endothelial growth factor (VEGF) and VEGF-C show overlapping binding sites in embryonic endothelia and distinct sites in differentiated adult endothelia. Circ. Res. 85:992-999.
22. Karkkainen, M.J., and Petrova, T.V. 2000. Vascular endothelial growth factor receptors in the regulation of angiogenesis and lymphangiogenesis. Oncogene. 19:5598-5605.
23. Skobe, M., et al. 2001. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat. Med. 7:192-198.
24. Koolwijk, P., et al. 2001. Involvement of VEGFR-2 (kdr/flk-1) but not VEGFR-1 (flt-1) in VEGF-A and VEGF-C-induced tube formation by human microvascular endothelial cells in fibrin matrices in vitro. Angiogenesis. 4:53-60.
25. Skobe, M., et al. 2001. Concurrent induction of lymphangiogenesis, angiogenesis, and macrophage recruitment by vascular endothelial growth factor-C in melanoma. Am. J. Pathol. 159:893-903.
26. Oh, S.J., et al. 1997. VEGF and VEGF-C: specific-induction of angiogenesis and lymphangiogenesis in the differentiated avian chorioallantoic membrane. Dev. Biol. 188:96-109.
27. Jeltsch, M., et al. 1997. Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. Science. 276:1423-1425.
28. Kaipainen, A., et al. 1995. Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. Proc. Natl. Acad. Sci. U. S. A. 92:3566-3570
29. Karpanen, T., et al. 2001. Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth. Cancer Res. 61:1786-1790.
30. Lee, J., et al. 1996. Vascular endothelial growth factor-related protein: a ligand and specific activator of the tyrosine kinase receptor Flt4. Proc. Natl. Acad. Sci. U. S. A. 93:1988-1992.
31. Witzenbichler, B., et al. 1998. Vascular endothelial growth factor-C (VEGF-C/VEGF-2) promotes angiogenesis in the setting of tissue ischemia. Am. J. Pathol. 153:381-394.
32. Pepper, M.S., Mandriota, SJ., Jeltsch, M., Kumar, V., and Alitalo, K. 1998. Vascular endothelial growth factor (VEGF)-C synergizes with basic fibroblast growth factor and VEGF in the induction of angiogenesis in vitro and alters endothelial cell extracellular proteolytic activity. J. Cell. Physiol. 177:439-452.
33. Eggert, A., et al. 2000. High-level expression of angiogenic factors is associated with advanced tumor stage in human neuroblastomas. Clin. Cancer Res. 6:1900-1908.
34. Wartiovaara, U., et al. 1998. Peripheral blood platelets express VEGF-C and VEGF which are released during platelet activation. Thromb. Haemost. 80:171-175.
35. Fielder, W., et al. 1997. Expression of FLT4 and its ligand VEGF-C in acute myeloid leukemia. Leukemia. 11:1234-1237.
36. Lee, R., Kermani, P., Teng, K.K., and Hempstead, B.L. 2001. Regulation of cell survival by secreted proneurotrophins. Science. 294:1945-1948.
37. Mumm, J.S., et al. 2000. A ligand-induced extracellular cleavage regulates gamma-secretase-like proteolytic activation of Notch 1. Mol. Cell. 5:197-206.
38. Bush, G., et al. 2001. Ligand-induced signaling in the absence of furin processing of Notch 1. Dev. Biol. 229:494-502.
39. Cui, Y., Jean, F., Thomas, G., and Christian, J.L. 1998. BMP-4 is proteolytically activated by furin and/or PC6 during vertebrate embryonic development. EMBO J. 17:4735-4743.
40. He, Y., et al. 2002. Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signalling. J. Natl. Cancer Inst. 94:819-825.
41. Kubo, H., et al. 2002. Blockade of vascular endothelial growth factor receptor-3 signaling inhibits fibroblast growth factor-2-induced lymphangiogenesis in mouse cornea. Proc. Natl. Acad. Sci. U. S. A. 99:8868-8873.
42. Makinen, T., et al. 2001. Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3. Nat. Med. 7:199-205.
43. Salven, P., et al. 1998. Vascular endothelial growth factors VEGF-B and VEGF-C are expressed in human tumors. Am. J. Pathol. 153:103-108.